Tela Bio Inc

NASDAQ TELA

Data sourced from

and

Download Data

Tela Bio Inc Return on Sales (ROS) 2 year CAGR for the year ending December 31, 2023: -19.29%

Tela Bio Inc Return on Sales (ROS) 2 year CAGR is -19.29% for the year ending December 31, 2023, a 11.48% change year over year. Return on sales (ROS) measures the profitability of a company relative to its revenue. It is calculated by dividing the net income by the revenue. This ratio indicates the company's profitability margin or the proportion of each dollar of revenue that translates into net income. A higher return on sales suggests better profitability and efficient cost management. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Tela Bio Inc Return on Sales (ROS) for the year ending December 31, 2022 was -107.05%, a 12.66% change year over year.
Tela Bio Inc Return on Sales (ROS) for the year ending December 31, 2021 was -122.56%, a 29.98% change year over year.
Tela Bio Inc Return on Sales (ROS) for the year ending December 31, 2020 was -175.03%, a -4.77% change year over year.
Tela Bio Inc Return on Sales (ROS) for the year ending December 31, 2019 was -167.05%, a 34.47% change year over year.

NASDAQ: TELA

Tela Bio Inc

CEO	Mr. Antony Koblish
IPO Date	Nov. 8, 2019
Location	United States
Headquarters	1 Great Valley Parkway, Malvern, PA, United States, 19355
Employees	227
Sector	Healthcare
Industry	Medical devices

Description

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Key trends